Martensen IP Delivers Critical Guidance to Help Innovative Businesses Avoid Hidden IP Pitfalls in Government Contracting
For innovative companies chasing Small Business Innovation Research (SBIR) Phase II or III awards, the excitement of securing government funding often overshadows a critical reality: your proposal may become more than a persuasive pitch. It can become a legally binding part of the contract.
This shift means the words you choose, the technical details you include, and even the way you structure your workforce can have long-term consequences for your intellectual property (IP) rights. These risks often go unnoticed until they resurface during investor due diligence, licensing negotiations, or high-stakes acquisitions.
Why the Risks Are So Subtle
Most proposals are drafted with a focus on technical merit, demonstrating capability, innovation, and a clear plan for execution. But in government contracting, terms like 'develop,' 'create,' or 'design' can carry specific regulatory meanings. Without realizing it, you may be granting the U.S. government rights that limit your ability to control, commercialize, or exclusively license your technology later.
The challenge is compounded by the complexity of the Federal Acquisition Regulation (FAR) and the Defense Federal Acquisition Regulation Supplement (DFARS). While these frameworks exist to define how government IP rights are determined, their specialized language and layered clauses are rarely second nature to business leaders or technical teams.
The Real-World Stakes
Consider the scenario of a growing tech startup that wins a Phase III award. On paper, it is a major milestone. But if the proposal language or contract terms unintentionally give the government broad rights, that startup's competitive advantage and even its valuation could take a hit. The problem is not theoretical; it has happened before.
Why This Matters Beyond Compliance
Protecting IP in the context of government contracts is not just about avoiding legal disputes. It is about preserving future opportunities. Whether your growth strategy includes private investment, licensing deals, or an eventual acquisition, maintaining control over your proprietary methods and data is a business imperative.
The good news is that these risks can be mitigated with foresight and the right guidance. It starts with understanding how proposal language shapes contractual obligations and how to align internal processes, documentation, and agreements to keep your IP secure.
This essential white paper uncovers:
Download the white paper to gain the knowledge you need to protect your innovation while still winning the government contracts that fuel your growth.
About Martensen IP
At the intersection of business, law and technology, Martensen understands the tools of IP. Martensen knows the business of IP. We understand the tech market, especially when the government is a customer, and we know how to plan, assess, and adjust. Patents, trademarks, copyrights, trade secrets, licenses are our tools.
https://www.martensenip.com
Martensen IP Media Contact
Source: Story.KISSPR.com
Release ID: 1753433
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
15 hours ago
- Associated Press
CHAMA Chairs Launches New Rugged Outdoor Hats
08/19/2025, Dallas, TX // KISS PR Brand Story PressWire // CHAMA Chairs is excited to announce the launch of its new hat collection, bringing the rugged spirit of its comfortable camping chairs into outdoor-ready lifestyle gear. Made for adventurers who value purpose-driven design, it redefines performance apparel for life on the move. Crafted with the same relentless grit that made CHAMA's comfortable camping chairs a staple at campsites and tailgates, the new hat collection brings that backcountry soul to everyday life. They are not just accessories. They are gear for those who live on the move. From the airflow-ready Chamahat – BLACK TRUCKER TRICOLOR LINEAR PATCH to the trail-toned Chamahat – TAN GREEN STACKED CACTUS, each hat strikes the perfect balance of utility, comfort, and street-ready style. 'From day one, we've focused on performance and lasting quality,' said a CHAMA Chairs spokesperson. 'Our customers trust our gear in wild terrain. Now they can take that same trust and wear it, whether they're off-roading, traveling, or kicking back at the ranch. These hats are more than accessories. They're expressions of a lifestyle.' Each hat in CHAMA's new collection is made with field-proven materials, intentional design choices, and a nod to the brand's Texas roots. The Chamahat - Blue Navy Rope, for example, brings vintage style and utility together with its structured build and all-season wearability. Just like CHAMA's core line of heavy-duty camping chairs, these outdoor hats are made to feel broken-in from day one, without compromising performance. But this launch isn't just a style move. It's a signal of what's ahead. With two to three additional launches planned by December 2025, CHAMA is doubling down on its mission to become more than a gear brand. It's carving out space in the lifestyle arena with products that carry the same DNA as its comfortable camping chairs: purpose-built, unapologetically rugged, and designed to travel as far as its users do. This expansion is less about reinventing the brand and more about revealing its full potential. Longtime fans now have more ways to bring CHAMA into their everyday lives, and that broader appeal is already gaining traction. The brand has appeared in top publications like Forbes, featured in its 'Mother's Day Gift Guide: Best Gifts for a Luxury Road Trip,' and Fortune 's '10 Gifts for Newlyweds Who Love the Outdoors.' CHAMA has also been spotlighted by Sporting Classics, CBS News, and Condé Nast Traveler. These placements signal a breakout from niche outdoor circles into the wider lifestyle space, solidifying CHAMA as a go-to for everyday adventurers. With its new line of outdoor hats, CHAMA Chairs continues the legacy it started with its comfortable camping chairs by providing rugged, functional gear that works in the field and looks great every day. This move into lifestyle apparel shows CHAMA's strong connection to its customers, who value reliability, style, and purpose in everything they use. As the brand expands beyond the campsite, its gear stays true to its core principles of durability, versatility, and a readiness for adventure. To learn more about CHAMA's full lineup of outdoor lifestyle products, visit About CHAMA Chairs LLC CHAMA Chairs LLC is an outdoor gear company based in Dallas, TX, best known for creating high-performance camping chairs. Today, its lineup includes lifestyle apparel and outdoor hats built for durability, comfort, and everyday style. Designed for hunters, overlanders, and adventurers, CHAMA creates gear that's made for the field but stylish enough for everyday life. ### Media Contact Chama Chairs LLC Address: 6125 Luther Ln, Dallas, TX 75225 Phone: (817) 253-4386 Website: newsroom: Source published by Submit Press Release >> CHAMA Chairs Launches New Rugged Outdoor Hats
Yahoo
a day ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.
